TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean SF‐36v2 MCS improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vision loss from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-observer reliability of sedation measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of cancers detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cytomegalovirus disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cytomegalovirus infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total coronary heart disease risk
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac deaths
Endpoint domain: Mortality/survival
Primary endpoint: Hand function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of ophthalmic examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vomiting and altered bowel habit
Endpoint domain: Adverse events/effects
Primary endpoint: Unfavourable outcome in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: technical survival rate
Endpoint domain: Mortality/survival
Primary endpoint: incidence of peritonitis
Endpoint domain: Adverse events/effects
Primary endpoint: mean percentage of body weight loss from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in body fatness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PIP(1) for detrusor contraction strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Defecation period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total bowel care time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: documentation of any smoking cessation treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cessation medication prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cessation counseling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procalcitonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in forced expiratory volume in 1 s (FEV1% predicted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of postoperative chylothorax
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality rate due to complications
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of MIDAS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in HIT-6 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Headache episodes and days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steroid sparing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DHD (Days of Hospitalization Due to Antibiotic Prescription)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: %RSP (Percentage of Rational Antibiotic Prescriptions)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean decrease in mammographic density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Carer abusive behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Need for recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCORAD index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Socially embarrassing behaviour (SBS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Interpersonal functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Feelings of fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of S100B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurologic outcome after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: DAS28 score at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonresponse according to EULAR criteria at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: equivalent efficacy to cisapride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Antibody response at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma concentrations of Sirt1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VZV-CMI response levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Process composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor necrosis factor‐α level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual analogue scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIVA at 60 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNVA at 40 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall physical fitness level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid peroxidation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte ATPase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: risk of stroke
Endpoint domain: Mortality/survival
Primary endpoint: mean percent reduction of the anterior capsule opening area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean RIF surface regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any breastfeeding at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative cognitive effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurotoxicity complaints
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary bladder temperature accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NHS costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction of postoperative inflammatory responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fibrosis over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of M72-specific CD4 T-cells expressing immune markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: suppression of erythema formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: increase in skin hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Continuous sick leave after 1 year
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: No reduction in pain after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No reduction in disability after 12 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hemodynamic depression
Endpoint domain: Adverse events/effects
Primary endpoint: Hypertension requiring treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Filter survival
Endpoint domain: Mortality/survival
Primary endpoint: Alteration of LV flow-volume pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of postdural puncture headache
Endpoint domain: Adverse events/effects
Primary endpoint: Overall assessment of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mean SIBDQ scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: salivary sIgA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: pro-inflammatory chemokines (Gro-alpha and Gro-beta) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-inflammatory chemokines (Angiogenin) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 30-day bleeding rate
Endpoint domain: Adverse events/effects
Primary endpoint: overall treatment effects (efficacy and safety) of iv rtPA in acute ischaemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in HRQOL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in ADAS-cog/11
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased mixed and central apnea events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time of SatO2 < 90% decreased
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease of SDNN and NN50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of missed injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of stay in the emergency department
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: mean time to the first operating room visit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: C max for omeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐∞ for omeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distant metastasis-free survival (DMFS)
Endpoint domain: Mortality/survival
Primary endpoint: MOSPM total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 antigen-specific CD4(+) T cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV-1 antigen-specific CD8(+) T cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Env-specific antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall efficacy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse drug reaction rate
Endpoint domain: Adverse events/effects
Primary endpoint: Neck circumference (NC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arousal frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BASDAI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BASFI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axial pain reduction (visual analogue scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pocket depth reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding on probing (BOP) sites reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean clinical attachment level (CAL) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False alarms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P3 ERP amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time till recurrence of mania
Endpoint domain: Mortality/survival
Primary endpoint: time till recurrence of depression
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of fracture of onlays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of onlays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of facial pressure injury
Endpoint domain: Adverse events/effects
Primary endpoint: Itch intensity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tactile sensitivity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Air blast sensitivity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversal of Minimal Hepatic Encephalopathy (MHE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence to yogurt supplementation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sexual function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measured drug adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychological disability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intrahepatic lipid (IHL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: skin temperature improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ankle-brachial pressure index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Shoulder abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BSHS-B
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: UEFI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: GST
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Pain reported by patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cost savings per patient
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: P1NP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: Bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: Increased CF (colonic fermentation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial bloating scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity >5 hours/week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of inflammatory markers (IL-6, TNF-alpha, CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Need for second procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Preference for method of abortion
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: 6-month disease control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: overall tumor response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative faecal recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fluorescein leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: additional treatments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: amelioration of keratinocytic and melanocytic atypia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: improvement in epidermal polarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: increase in epidermal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Omega-3 index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities of daily living (ADLs)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Stroke within 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Retention of orthodontic treatment results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived fatigue level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of adequate compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain during defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resume work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Total costs incurred
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Weight loss maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in Fugl-Meyer score in the paralyzed arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in spasticity as measured on the Modified Ashworth Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: metabolic outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: risk of coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: costs incurred by intervention group
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: tolerability of SLIT-tablets
Endpoint domain: Adverse events/effects
Primary endpoint: oral site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean reduction in nocturnal voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean reduction in diurnal voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean percent reduction in nocturnal urge urinary incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: gray-to-white SVD-CBF ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of uncovered struts per stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Neointimal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mean number of bleeding days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: mean number of spotting days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: proportion of infants with a treated patent ductus arteriosus or death at <28 days of age
Endpoint domain: Mortality/survival
Primary endpoint: Sleep improvement
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Episodic memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visuospatial abilities enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: nerve regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ocular surface stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regional systolic LV function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Parasympathetic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRRtau
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries inhibition efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal adaptation of vertical enamel margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal adaptation in dentine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of excellent margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes